Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2017-10-23 Legal Proceedings Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AZ and MSD rapidly advance Lynparza in Japan
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 2987U' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange'. This strongly indicates the document is a regulatory news service announcement. The content details a regulatory submission (NDA) for a drug (Lynparza) in Japan, which is a corporate update related to operations and regulatory progress, not a full financial report (like 10-K or IR) or a specific management/board change. Since it is a general regulatory announcement distributed via the RNS system and doesn't fit perfectly into categories like ER, DIV, or MANG, the most appropriate classification is the general regulatory filing category, RNS.
2017-10-23 English
US FDA approves Bydureon BCise for type-2 diabetes
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated October 23, 2017. The content is a press release announcing that the US FDA has approved a new medicine (Bydureon BCise) for Type-2 diabetes. This is a significant corporate announcement regarding product approval and market access, but it is not a formal financial report (like 10-K or IR), a management discussion (MDA), or a transcript (CT). Since it is a general regulatory announcement disseminated via the London Stock Exchange's news service (RNS), and it doesn't fit neatly into the other specific categories (like DIV, CAP, or ER which focus purely on financials/shareholder actions), the most appropriate classification is the general regulatory announcement category, RNS.
2017-10-23 English
6-K Filing
Regulatory Filings
2017-10-23 English
6-K Filing
Regulatory Filings
2017-10-23 English
FDA Priority Review for Lynparza in breast cancer
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8809T' and is dated '18 October 2017'. It announces a significant regulatory event: the US FDA accepting a regulatory submission for Lynparza and granting Priority Review. This type of announcement, which disseminates material, non-public information to the market via an official channel (RNS), fits the description of a general regulatory announcement. Since it is not a full financial report (like 10-K or IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such market disclosures distributed through the RNS system.
2017-10-18 English
6-K Filing
Regulatory Filings
2017-10-18 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.